Adiposs secures CHF 4 millions in Series A
Adiposs SA, a Geneva-based clinical-stage Swiss life sciences company announced the successful closing of a CHF 4 million Series A financing round.
Adiposs is pioneering the development of the first imaging product for brown fat designed to predict response to cancer therapy and enable personalized cancer treatment at scale. The financing will be used for proof-of-principle clinical development of Adiposs’ first-in-class asset, ImageBAT®, a novel contrast agent designed for non-invasive CT imaging of brown fat in cancer patients, which cannot be reliably achieved today. This milestone marks a significant step toward addressing a critical unmet medical need in oncology: identifying non-responding cancer patients early.
10 Jul 2025